Inmazeb is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire …

Atoltivimab/maftivimab/odesivimab, sold under the brand name INMAZEB, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus (Ebola virus). …

2020年10月14日，再生元（Regeneron）近日宣布，美国食品药品监督管理局（FDA）已批准Inmazeb（atoltivimab、maftivimab、odesivimab-ebgn，前称REGN-EB3）用于治疗埃博拉 …

INMAZEB is a combination of Zaire ebolavirus glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), indicated for the treatment of...

2020年11月2日 · 2020年10月14日，再生元（Regeneron）近日宣布，美国食品药品监督管理局（FDA）已批准Inmazeb（atoltivimab、maftivimab、odesivimab-ebgn，前称REGN-EB3） …

Inmazeb是由3种全人IgG1单抗组成的混合物，由再生元利用专有的VelociSuite®快速反应技术开发，目前该技术正被应用于开发针对新型冠状病毒肺炎（COVID-19）的新型抗体鸡尾酒疗法。

INMAZEB is a combination of Orthoebolavirus zairense glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), indicated for the treatment of infection …

2024年12月23日 · INMAZEB is a combination of Orthoebolavirus zairense glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), indicated for the …

INMAZEB is a drug used to treat pediatric and adult patients who have an infection caused by Zaire ebolavirus. Zaire ebolavirus infection (sometimes called Ebola or Ebola virus disease) is a...

Atoltivimab/ maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved treatment for Zaire ebolavirus infection in adult and pediatric patients, including …